Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 8,500 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $33.19, for a total transaction of $282,115.00. Following the transaction, the chief financial officer now owns 102,464 shares in the company, valued at $3,400,780.16. This represents a 7.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $34.90 on Friday. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47. The stock has a market capitalization of $6.64 billion, a PE ratio of -12.25 and a beta of 1.07. The company’s 50 day simple moving average is $32.68 and its two-hundred day simple moving average is $28.29.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to analysts’ expectations of $4.04 million. On average, research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Wall Street Analysts Forecast Growth

BBIO has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a report on Thursday, February 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. Evercore ISI increased their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, December 23rd. Bank of America increased their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. Finally, Scotiabank upped their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $51.67.

Institutional Trading of BridgeBio Pharma

Hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC lifted its stake in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after purchasing an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of BridgeBio Pharma in the fourth quarter valued at about $41,000. Sterling Capital Management LLC increased its position in shares of BridgeBio Pharma by 554.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock valued at $49,000 after acquiring an additional 1,514 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of BridgeBio Pharma in the fourth quarter valued at about $109,000. Finally, Advisors Asset Management Inc. increased its position in shares of BridgeBio Pharma by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after buying an additional 1,645 shares during the period. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.